netFormulary NHS
Lancashire and South Cumbria
Formulary
 Search
 Results

Looking for Denosumab found 20 matches

Formulary items 2 matches
Sub Section Title / notes 1 match
   
Open monograph to display formulary status BNF Category
  Denosumab  (Prolia®) Endocrine system - Denosumab - 06.06.02
  Denosumab  (XGEVA®) Endocrine system - Denosumab - 06.06.02
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section LSCMMG: Denosumab 120mg injection (Xgeva®) shared care guideline (06.06.02)
link in drug section LSCMMG: Denosumab 60mg injection (Prolia®) shared care guideline (06.06.02)
link in drug section LSCMMG: Denosumab as a second line treatment option for the prevention of osteoporotic fragility fractures position statement (06.06.02)
link in drug section MHRA Drug Safety Update Aug 2020: Denosumab 60mg (Prolia): increased risk of multiple vertebral fractures after stopping or delaying ongoing treatment (06.06.02)
link in drug section MHRA Drug Safety Update June 2017: Denosumab (Prolia, Xgeva): reports of osteonecrosis of the external auditory canal (06.06.02)
link in drug section MHRA Drug Safety Update June 2017: Denosumab (Prolia, Xgeva): reports of osteonecrosis of the external auditory canal (06.06.02)
link in drug section MHRA Drug Safety Update June 2018: Denosumab (Xgeva) for advanced malignancies involving bone: study data show new primary malignancies reported more frequently compared to zoledronate (06.06.02)
link in drug section MHRA Drug Safety Update June 2018: Denosumab (Xgeva) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation  (06.06.02)
link in drug section MHRA Drug Safety Update May 2022: Denosumab 60mg (Prolia): should not be used in patients under 18 years due to the risk of serious hypercalcaemia (06.06.02)
link in drug section MHRA: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk (06.06.02)
link in drug section MHRA: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk (06.06.02)
link in drug section MHRA: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk (06.06.02)
link in drug section MHRA: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk (06.06.02)
link in drug section MHRA: Denosumab: updated recommendations (06.06.02)
link in drug section MHRA: Denosumab: updated recommendations (06.06.02)
link in drug section NICE TA204: Osteoporotic fractures - denosumab  (06.06.02)
link in drug section NICE TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (06.06.02)

SubSection Titles / notes  
Denosumab - (06.06.02)



Document Library Items Found
Document links Shared Care Guidelines (Denosumab 120mg shared care guideline)
Document links Shared Care Guidelines (Denosumab 60mg shared care guideline)
Document links All Pathways and Guidance (Denosumab: Position Statement)

 
netFormulary